Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.

You may also be interested in...



Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.

Humabs BioMed Seeking Clinical Development Partner For ‘Natural Selection’ MAbs

Novartis and MedImmune have over the past several months also started clinical studies of antibodies licensed from the Swiss biotech, which derives its products from patients with highly effective immune responses.

AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million

The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel